STOCK TITAN

SpyGlass Pharma (SGP) Stock Price, News & Analysis

SGP NASDAQ
Published by Stock Titan Data refreshed

Price Move History

Daily moves over 5%
27 196 sessions, February 6, 2026 to November 16, 2026
Largest daily move
+15% close of April 13, 2026
1-month change
+34.3% closing prices, October 16, 2026 to November 16, 2026

Company Description

SpyGlass Pharma (NASDAQ: SGP) is classified in the biotechnology industry within the Healthcare sector and carries a market capitalization of $1.1B.

SGP has gained 34.3% over the past month. The last closing price was $32.24.

For FY2025, SpyGlass Pharma reported net income of -$39.9M and diluted earnings per share of -$17.98.

This page collects what Stock Titan holds for SGP, including price data, latest news, SEC filings, financial highlights, upcoming events, and short interest trends.

Stock Performance

$32.24
-1.95%
-0.64
Last updated: November 16, 2026 at 16:00
+34.3%
Performance 1 month

SpyGlass Pharma (SGP) closed at $32.24 on November 16, 2026. Over the past month, the price has gained 34.3%.

See what a $1,000 investment in SGP would be worth today

Average down calculator for SGP

SGP Metrics & Rankings

Price returns through November 16, 2026. Month and year figures include the first trading day. Ranking links may use different dates.

Financial Highlights

SpyGlass Pharma reported operating income of -$41.4M in FY2025, and net income was -$39.9M. Diluted earnings per share stood at -$17.98. The company generated -$32.7M in operating cash flow. The current ratio was 12.67, measuring current assets divided by current liabilities.

-$39.9M
Net Income (FY2025)
-$32.7M
Operating Cash Flow
—
Revenue (FY2025)

Upcoming Events

NOV
17
November 17, 2026 Marketing

Jefferies fireside chat

Fireside chat and one-on-one meetings at Jefferies, London on Nov 17, 2026. Live webcast and replay on Investor Relations site.
DEC
03
December 3, 2026 Marketing

Citi fireside chat

Fireside chat and one-on-one meetings at Citi, Miami on Dec 3, 2026. Live webcast and replay on Investor Relations site.
YEAR
2027
2027 Clinical

Phase 3 enrollment completion

Enrollment completion expected for Phase 3 BIM-IOL trials SGP-005 and SGP-006; surgeries have begun; 2027 timeframe.

SpyGlass Pharma has 3 upcoming scheduled events. The next event, "Jefferies fireside chat", is scheduled for November 17, 2026 (tomorrow). Investors can track these dates to stay informed about potential catalysts that may affect the SGP stock price.

Short Interest History

Last 12 Months

Short interest in SpyGlass Pharma (SGP) currently stands at 1.2 million shares, down 5.2% from the previous reporting period, representing 3.6% of the float. Since February 2026, short interest has increased by 541.0%.

Days to Cover History

Last 12 Months

Days to cover for SpyGlass Pharma (SGP) currently stands at 12.1 days, down 23% from the previous period. The ratio is the reported short interest divided by the average daily trading volume. Since February 2026, the figure has increased by 1005.5%. Across the settlements charted above, it has ranged from 1.1 to 19.4 days.

SGP Company Profile & Sector Positioning

SpyGlass Pharma (SGP) operates in the Biotechnology industry within the broader Healthcare sector and is listed on the NASDAQ.

Investors comparing SGP often look at related companies in the same sector, including Mentari Therapeutics, Inc. (MTRI), Seaport Therapeutics, Inc. (SPTX), MoonLake Immunotherapeutics (MLTX), Vor Biopharma Inc. (VOR), and Alto Neuroscience Inc. (ANRO). Comparing financial metrics, valuation ratios, and stock performance across these peers can help investors evaluate SGP's relative position within its industry.

Frequently Asked Questions

The current stock price of SpyGlass Pharma (SGP) is $32.24 as of November 16, 2026.

The market cap of SpyGlass Pharma (SGP) is approximately $1.1B. Learn more about what market capitalization means .

The FY2025 net income of SpyGlass Pharma (SGP) is -$39.9M, from its most recent completed fiscal year.

The diluted earnings per share (EPS) of SpyGlass Pharma (SGP) is -$17.98 for FY2025, its most recent completed fiscal year. Learn more about EPS .

The operating cash flow of SpyGlass Pharma (SGP) is -$32.7M for FY2025, its most recent completed fiscal year. Learn about cash flow.

The current ratio of SpyGlass Pharma (SGP), current assets divided by current liabilities, was 12.67 at the end of FY2025, its most recent completed fiscal year. Learn about liquidity ratios.

The operating income of SpyGlass Pharma (SGP) is -$41.4M for FY2025, its most recent completed fiscal year. Learn about operating income.